The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1463
ISSUE1463
March 2, 2015
An Inhaled Insulin (Afrezza)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
An Inhaled Insulin (Afrezza)
March 2, 2015 (Issue: 1463)
The FDA has approved an inhaled, rapid-acting, dry-powder
formulation of recombinant human insulin
(Afrezza – Mannkind/Sanofi) for treatment of adults
with type 1 or type 2 diabetes. In patients with type 1
diabetes, the drug must be used in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.